Seak Therapeutics, LLC

Memphis, TN

UEI
HBTSD5J8NL84
CAGE
87ZA7
Primary NAICS
Not on record
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Limited Liability Company
Entity structure
Sole Proprietorship
SAM.gov registration date
Physical address
881 Madison Ave #561, Memphis, TN 38163, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Development of a potent and highly brain-penetrable antimitotic agent SEAK193 to treat breast cancer brain metastasis R41CA310186 National Cancer Institute (NIH) $399,981
Developing a selective TRPC3 ION channel inhibitor for epilepsy treatment R41NS135658 National Institute of Neurological Disorders and Stroke (NIH) $429,932
Feasibility study of developing seak-114 for the treatment of pediatric cancers R43CA257324 National Cancer Institute (NIH) $399,964
Development of a dual MDM2/xiap inhibitor with a high therapeutic index for childhood cancers R43CA246788 National Cancer Institute (NIH) $354,823

Similar vendors

Vendor Location Primary NAICS
Atux Iskay Group LLC UEI C7JPQ5F3UUH7 Plainsboro Township, NJ 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Immunochem Therapeutics LLC UEI SCDHKSSUC4T4 Newton, MA 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Cornovus Pharmaceuticals Inc. UEI EBD9Y2Q2JW55 New Haven, CT 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Triterpenoid Therapeutics Inc. UEI JA25GYTMYJP3 Boston, MA 813920 Professional Organizations
Quercus Molecular Design, LLC UEI ZHH5N3KV48A5 Avon, CT 541714 Research and Development in Biotechnology (except Nanobiotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Seak Therapeutics, LLC is a for-profit, limited liability company and sole proprietorship registered to receive federal grants and contracts. Based on its name, it appears to be a biotechnology or pharmaceutical company focused on developing therapeutic drugs and treatments.

Seak Therapeutics has received several grants from the National Institutes of Health (NIH) to fund drug development research projects. In 2023, it was awarded a $429,932 grant from the NIH's National Institute of Neurological Disorders and Stroke to develop a selective inhibitor of the TRPC3 ion channel called JW-65 as a potential treatment for epilepsy. The project involves comprehensive evaluation of JW-65's safety, pharmacokinetics, and efficacy in suppressing acute seizures in rodent models. Earlier, in 2020, Seak received two grants totaling $754,787 from the NIH's National Cancer Institute. One grant for $399,964 aimed to study the feasibility of developing SEAK-114 for treating pediatric cancers. The other $354,823 grant supported the development of a dual MDM2/XIAP inhibitor with a high therapeutic index for childhood cancers. Seak Therapeutics appears to specialize in early-stage drug discovery and preclinical development, particularly for neurological disorders and cancers, by leveraging federal funding from the NIH.

Quick answers

Is Seak Therapeutics, LLC registered in SAM.gov?

Yes. Seak Therapeutics, LLC's SAM.gov registration is active through August 16, 2027.

What is Seak Therapeutics, LLC's CAGE code?

Seak Therapeutics, LLC's CAGE code is 87ZA7, and its Unique Entity ID (UEI) is HBTSD5J8NL84.

What is Seak Therapeutics, LLC's most recent federal award?

Seak Therapeutics, LLC's most recent federal grant award is Development of a potent and highly brain-penetrable antimitotic agent SEAK193 to treat breast cancer brain metastasis (R41CA310186), from National Cancer Institute (NIH), on September 19, 2025.

On GovTribe

See Seak Therapeutics, LLC's full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login

Find teaming partners on GovTribe